Among the soluble factors that regulate skeletal muscle function, Transforming Growth Factor
type Beta 1 (TGF-β1) is one of the most studied. This factor inhibits myogenesis and regeneration by
regulating the activity and function of satellite cells (SCs). Indeed, TGF-β has a central role in muscle
pathologies in which there is development of fibrosis and/or atrophy of skeletal muscle. Thus, in this
review we present the critical and recent antecedents regarding the mechanisms and cellular targets involved
in the effects of TGF-β1 in the muscle, in pathological processes such as the inhibition of regeneration,
fibrosis and atrophy. In addition, an update on the development of new strategies with therapeutic
potential to inhibit the deleterious actions of TGF-β in skeletal muscle is discussed.
Keywords: Muscle atrophy, fibrosis, dystrophy, renin angiotensin system, blocking antibodies, therapy.
Rights & PermissionsPrintExport